Recent Updates
Recently added Catalysts
CRIS

Bertoni F., CA-4948 BTKi Synergy AACR-NCI-EORTC 2023

Monday, December 11, 2023 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products including Emavusertib (CA-4948). It highlights the company's focus on various lymphoma studies and its commitment to patient care through compassionate use policies. Additionally, it includes information on investor relations and corporate governance.

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What is the focus of Curis, Inc.?

Curis, Inc. focuses on developing innovative therapies for cancer, particularly lymphomas.

What products are included in Curis' pipeline?

Curis' pipeline includes Emavusertib (CA-4948), Fimepinostat, CA-170, and CA-327.

What studies are sponsored by Curis?

Curis sponsors studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

How does Curis support patients?

Curis supports patients through compassionate use policies and ongoing clinical studies.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Curis CA-4948 lymphoma clinical studies biopharma
Last updated: Dec 11, 2023

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →